研究单位：[1]Tianjin Medical University Cancer Institute & Hospital[2]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,233099[4]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,Guangzhou,Guangdong,China,511399[5]The Affiliated Cancer Hospital of Guizhou Medical University,Guiyang,Guizhou,China,550000[6]Affiliated Hospital of Hebei University,Baoding,Hebei,China[7]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430060[8]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China[9]Yibin Second People's Hospital,Yibin,Sichuan,China,644199[10]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China
研究目的：
This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in subjects with advanced solid tumor.
